Kosmos Energy Ltd. Common Shares (DE) vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Kosmos Energy Ltd. Common Shares (DE) trades at $2.71 (market cap $1.66B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.78 (market cap $2.51B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and Kosmos Energy Ltd. Common Shares (DE) is more actively traded (7,535,344 versus 6,359,048). Which is the better fit depends on your goals — on Pluang, investors hold Kosmos Energy Ltd. Common Shares (DE) for 0 Days and SELLAS Life Sciences Group Inc. Common Stock for 0 Days on average.
| KOS | SLS | |
|---|---|---|
Market Cap | $1.66B | $2.51B |
Volume | 7,535,344 | 6,359,048 |
Sector | Energy | Health |
52-Week High | $3.27 | $15.46 |
52-Week Low | $0.87 | $1.39 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.30B | $2.37B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SELLAS Life Sciences (SLS) trades at $12.41, up 4.02% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported no revenue in 2025, with a net loss of $26.86 million, negative ROE and ROA, and a high P/B ratio of 18.2. Recent news includes a law firm investigation into investor claims and positive preclinical data for SLS009 in pancreatic cancer models presented at the AACR conference.
The outlook hinges on upcoming clinical trial results, particularly the Phase 3 REGAL trial for GPS in AML, with topline data expected in Q4 2026. While analyst consensus is unanimously bullish, significant risks include the binary nature of trial outcomes, ongoing legal scrutiny, and persistent negative profitability metrics. The stock's recent surge of ~300% year-to-date reflects high investor optimism but also heightened volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kosmos Energy Ltd. is a deepwater oil and gas exploration and production company with operations offshore Ghana, Equatorial Guinea, Mauritania, and Senegal in West Africa.
Read more on KOS →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →